151 related articles for article (PubMed ID: 16024942)
1. Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B.
Nakanishi H; Kurosaki M; Asahina Y; Onuki Y; Ueda K; Nishimura Y; Tsuchiya K; Kitamura T; Uchihara M; Miyake S; Enomoto N; Izumi N
Intervirology; 2005; 48(6):381-8. PubMed ID: 16024942
[TBL] [Abstract][Full Text] [Related]
2. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
3. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
4. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B.
Ogata N; Fujii K; Takigawa S; Nomoto M; Ichida T; Asakura H
J Med Virol; 1999 Nov; 59(3):270-6. PubMed ID: 10502255
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
[TBL] [Abstract][Full Text] [Related]
6. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
7. Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase.
Fukai K; Zhang KY; Imazeki F; Kurihara T; Mikata R; Yokosuka O
J Viral Hepat; 2007 Sep; 14(9):661-6. PubMed ID: 17697019
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of lamivudine-resistant hepatitis B virus (HBV) strains with and without breakthrough hepatitis in patients with chronic hepatitis B evaluated by serial HBV full-genome sequences.
Horiike N; Duong TN; Michitaka K; Joko K; Hiasa Y; Konishi I; Yano M; Onji M
J Med Virol; 2007 Jul; 79(7):911-8. PubMed ID: 17516520
[TBL] [Abstract][Full Text] [Related]
9. Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy.
Akuta N; Suzuki F; Kobayashi M; Matsuda M; Sato J; Takagi K; Tsubota A; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2003 Dec; 71(4):504-10. PubMed ID: 14556262
[TBL] [Abstract][Full Text] [Related]
10. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
Liang WF; Yang DH; Shen YH; Xie YJ; Zhao NF
Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
[TBL] [Abstract][Full Text] [Related]
11. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
[TBL] [Abstract][Full Text] [Related]
12. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y
Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
[TBL] [Abstract][Full Text] [Related]
13. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
[TBL] [Abstract][Full Text] [Related]
14. Viral features of lamivudine resistant hepatitis B genotypes A and D.
Zöllner B; Petersen J; Puchhammer-Stöckl E; Kletzmayr J; Sterneck M; Fischer L; Schröter M; Laufs R; Feucht HH
Hepatology; 2004 Jan; 39(1):42-50. PubMed ID: 14752821
[TBL] [Abstract][Full Text] [Related]
15. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?
Lee GH; Aung MO; Dan YY; Lee YM; Mak B; Low HC; Lim K; Thwin MA; Tan PS; Lim SG
J Med Virol; 2013 Jan; 85(1):26-33. PubMed ID: 23023992
[TBL] [Abstract][Full Text] [Related]
16. [Polymerase region mutations and hepatitis B virus genotypes in chronic hepatitis B patients with poor response to lamivudine].
Xu LJ; Pan C; Li QG; Chen RH; Zheng L; Zhang QY; Chen HC
Zhonghua Gan Zang Bing Za Zhi; 2010 Mar; 18(3):180-3. PubMed ID: 20380793
[TBL] [Abstract][Full Text] [Related]
17. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
18. [Detection and analysis of the new kind of G743C and G743A point mutation of HBV P gene in hepatitis B virus infected patients resistant to lamivudine].
Pan XP; Wo JE; Chen Z; Chen F; Liang WF; Liu KZ
Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):616-8. PubMed ID: 14572341
[TBL] [Abstract][Full Text] [Related]
19. HBV mutations associated with lamivudine therapy.
Lapiński TW; Parfieniuk-Kowerda A; Trzos A; Jaroszewicz J; Kowalczuk O; Nikliński J; Flisiak R
Przegl Epidemiol; 2013; 67(4):611-6, 705-8. PubMed ID: 24741905
[TBL] [Abstract][Full Text] [Related]
20. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K
J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]